Related Experiment Video
Updated: Jan 10, 2026

Biochemical and Structural Characterization of the Carbohydrate Transport Substrate-binding-protein SP0092
Published on: October 2, 2017
Structural and Biophysical Basis for PFAS Binding by Human Sterol Carrier Protein-2.
Aaron S Birchfield1, Rachel L Signorelli1, Kyla T Cang1
1Department of Chemistry, Virginia Commonwealth University, Richmond, VA 23284, U.S.A.
This study reveals that sterol carrier protein 2 (SCP2) binds to harmful per- and polyfluoroalkyl substances (PFAS). This discovery suggests a broader network of lipid-binding proteins contributes to PFAS distribution and persistence in the human body.
Area of Science:
- Environmental Science
- Biochemistry
- Toxicology
Background:
- Per- and polyfluoroalkyl substances (PFAS) are persistent environmental contaminants with known adverse health effects.
- PFAS bioaccumulate in human tissues and bind to various lipid-binding proteins (LBPs).
- The full extent of PFAS interaction with LBPs and its role in biological distribution remains unclear.
Purpose of the Study:
- To investigate the interaction between PFAS and human sterol carrier protein 2 (SCP2), a novel LBP candidate.
- To explore the molecular basis of PFAS binding to LBPs.
- To support the hypothesis that a network of LBPs facilitates PFAS distribution and persistence.
Main Methods:
- Screening assays to identify potential PFAS-SCP2 interactions.
- Fluorescence displacement assays to quantify binding affinity.
- Protein structure prediction to model PFAS-SCP2 complexes.
- Nuclear Magnetic Resonance (NMR) experiments to confirm interactions and identify binding sites.
Main Results:
- Sterol carrier protein 2 (SCP2) demonstrates direct binding with various PFAS.
- Key amino acid residues involved in the PFAS-SCP2 interaction were identified.
- The findings provide structural insights into how SCP2 binds to PFAS.
Conclusions:
- SCP2 is identified as a novel PFAS-binding protein.
- This expands the known repertoire of LBPs interacting with PFAS.
- The results support the hypothesis of a distributed LBP network mediating PFAS transport and persistence in humans.
Related Concept Videos
Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion,...
Lipids as Anchors
The carboxy-terminal of most of the prenylated proteins, such as Ras proteins, contains...
Factors Affecting Protein-Drug Binding: Drug-Related Factors
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
Regulation of Nuclear Protein Sorting
Drug Binding to Blood Components
HSA is the most abundant plasma protein and is vital in drug binding. It contains distinct drug-binding sites, with different drugs exhibiting affinity for specific sites. There are three main drug-binding domains for HSA: sites I, II, and III. These domains are...

